DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* INNAVIRVAX *


 

2008 - IDF
Évry
(near Paris)
www.innavirvax.fr

 

Discovery, Immunology
(also, Discovery, Diagnostics)
Key words: HIV, CD4 restoration, Predictive test
Mission: to develop a new HIV therapeutic vaccine aiming to restore CD4 to normal levels (without immunodeficiency) and to design a diagnostics test able to predict the evolution of the AIDS pathology of a given patient
Clients: Pharmaceutical industry
joelcrouzet@innavirvax.fr

Age: 9 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Crouzet (Joël) [born 1958, Ph.D., Eng. Agro (Grignon), ex-Eurobiobiz, Inserm Transfert, Neurotech, APCells, Rhône-Poulenc Rorer]
Sc.Dir.-CSO: Crouzet (Joël)
Fin.Dir.-CFO:
Proj.Mgr.: Ho Tsong Fang (Raphaël) [Vet.D., Ph.D. microbiology and medical virology, ex-Institut Pasteur, UCLA (Los Angeles)]
Financers (Hist.): Pradeyrol Développement, Fa Dièse, CapDecisif Management, Genopole 1er Jour

Turnover (M€) : n.a.
Total funding (M€) : 6.4
Last funding (M€) : 3.7
Focus : HIV
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .03 Clinical trial (phase I/IIa) for VAC-3S, a novel immunotherapy for the treatment of HIV-1 infections (beginning), with a grant of 0.6 M€ from OSEO CLIN [4 years]
2012 .02 2nd round-financing : 3.7 M€, led by the Pradeyrol Développement family office along with the private equity fund Fa Dièse, the FRCI, and the historical investors managed by CapDecisif Management RFINB [3 years]
2010 .01 Research : selection of VAC3S its first vaccine candidate for development and initiation of non clinical development (toxicology studies started in January 2011, ended June) R&D [1 year]
2009 .06 1st round-financing : 1.1 M€, by Cap Décisif Management and Genopole 1er Jour RFINA [1 year]
2008 .07 Seed financing : 0.45 M€, as a grant by French Ministry of Research and Higher Education (followed by a grant of 1.15 M€ by ANR) SFIN [0 year]
2008 .03 Company founded by undisclosed entrepreneurs, based on research by Prof. Patrice Debré and Dr Vincent Vieillard (INSERM U945, AP-HP Pitié-Salpétrière, University Pierre & Marie Curie) ORGF [0 year]

Actualisation / Updating: 16-Mar-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende